National Academies Press: OpenBook

Vaccines for the 21st Century: A Tool for Decisionmaking (2000)

Chapter: Appendix 1: Borrelia burgdorferi

« Previous: References
Suggested Citation:"Appendix 1: Borrelia burgdorferi." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

APPENDIX 1
Borrelia burgdorferi

DISEASE BURDEN

Epidemiology

For the purposes of the calculations in this report, the committee estimated that there are 12,000 new cases of infection each year in the United States. The risk of borrelia infection is highest in certain regions of the United States, such as, New England, the Mid-Atlantic states, and certain areas in the Midwest. The committee assumed that within epidemic regions new infections occur equally in males and females and that there are no deaths. The incidence rate is 4.56 per 100,000, but varies slightly by age group. The highest incidence is estimated to occur in the age groups that spend the most amount of time out of doors, that is, those up to 14 years of age. Table A1–1 illustrates the age distribution of new cases of borrelia infection used in the model. Approximately half of all new infections are assumed to occur in people born in the region and half in migrants into the area.

Disease Scenarios

For the purposes of the calculations in this report, the committee assumed that 90% of people newly infected with borrelia experience acute manifestations and seek treatment. The morbidity results in 3 weeks of minor illness associated with a health utility index (HUI) of .89. Another 2% of the new infections experience the same acute illness but do not seek treatment. The committee estimated that 8% of all new infections lead to chronic morbidity expressed as recurrences over a long period of time. The committee estimated that such people experience approximately 2 months per year of illness associated with a HUI of .79 and that

Suggested Citation:"Appendix 1: Borrelia burgdorferi." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

Table A1–1 Incidence Rates—Borrelia burgdorferi

5-Year Age Groups

Total Population

Incidence Rates (per 100,000) (5-yr age groups)

Cases

Age Groups

Population

Incidence Rates (per 100,00)

0–4

20,182,000

4.95

998

<1

3,963,000

4.95

5–9

19,117,000

4.95

945

1–4

16,219,000

4.95

10–14

18,939,000

4.95

937

5–14

38,056,000

4.95

15–19

17,790,000

4.27

759

15–24

36,263,000

4.27

20–24

18,473,000

4.27

789

25–34

41,670,000

4.27

25–29

19,294,000

4.27

824

35–44

42,149,000

4.88

30–34

22,376,000

4.27

955

45–54

30,224,000

4.61

35–39

22,215,000

4.88

1,084

55–64

21,241,000

4.27

40–44

19,934,000

4.88

973

65–74

18,964,000

4.27

45–49

16,873,000

4.88

823

75–84

11,088,000

4.27

50–54

13,351,000

4.27

570

• 85

3,598,000

4.27

55–59

11,050,000

4.27

472

60–64

10,191,000

4.27

435

Total

263,435,000

4.56

65–69

10,099,000

4.27

431

70–74

8,865,000

4.27

378

75–79

6,669,000

4.27

285

80–84

4,419,000

4.27

189

• 85

3,598,000

4.27

154

Total

263,435,000

 

12,000

Suggested Citation:"Appendix 1: Borrelia burgdorferi." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

these recurrences occur for 10 years. Table A1–2 summarizes the disease scenarios associated with borrelia infections.

COST INCURRED BY DISEASE

Health care costs are incurred through diagnostic evaluation, physician visits, and antibiotics. Table A1–3 summarizes the health care costs incurred by borrelia infections. For the purposes of the calculations, it was assumed that all people with acute manifestations incur two physician visits and a prescription antibiotic, and that half receive diagnostic tests. It was assumed that each recurrence is associated with two physician visits and a prescription medication, and that the recurrences occur for 10 years.

VACCINE DEVELOPMENT

The committee assumed that the development of a Borrelia burgdorferi vaccine is feasible and that licensure is imminent (a Borrelia vaccine for use in persons 15 years of age and older was licensed prior to the completion of this report). The estimates for this report are that it will take 3 years until licensure is completed and that $120 million needs to be invested. Table 4–1 summarizes vaccine development assumptions for all vaccines considered in this report.

VACCINE PROGRAM CONSIDERATIONS

Target Population

The committee’s analysis assumes that immunization with this vaccine will occur only in those geographic regions discussed under the epidemiology section. Immunization will occur during infancy or within 1 year of migration to the area. It is estimated that 90% of infants will receive the immunization. The committee estimates that only 10% of migrants into an area will receive the immunization.

Vaccine Schedule, Efficacy, and Costs

The committee estimated that this vaccine would cost $100 per dose. Vaccine administration would cost an additional $10. The committee has accepted default assumptions for this vaccine that estimate it will require a series of 3 doses and that efficacy will be 75%. Table 4–1 summarizes vaccine program assumptions for all vaccines considered in this report.

Suggested Citation:"Appendix 1: Borrelia burgdorferi." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

Table A1–2 Borrelia burgdorferi

 

No. of Cases

% of Cases

Committee HUI Values

Duration (years)

 

MORBIDITY SCENARIOS

 

 

Total Deaths

0

 

 

Total Cases

12,000

 

I.

Patients who receive treatment

 

90%

 

 

Acute manifestations

 

0.89

0.0575 (3 weeks)

II.

Untreated patients—no recurrence

 

2%

 

 

Acute manifestations

 

0.89

0.0575 (3 weeks)

III.

Complications in untreated patients—recurrences

 

8%

 

 

Acute manifestations

 

0.89

0.0575 (3 weeks)

 

Recurrences (over 10 years)

 

0.79

0.1667 (2 months/year over 10 years)

Table A1–3 Health Care Costs—Borrelia burgdorferi

 

Duration (years)

% with Care

Cost per Case

Cost per Unit

Units per Case (or per year)

Form of Treatment

I.

Patients who receive treatment

 

Acute manifestations

0.0575

100%

$100

$50

2.0

Physician A

0.0575

100%

$50

$50

1.0

Medication B

0.0575

50%

$100

$100

1.0

Diagnostic B

II.

Complications in untreated patients—recurrences

 

(2 months per year over 10 years)

10,000

100%

$100

$50

2.0

Physician A

 

100%

$50

$50

1.0

Medication B per recurrence

Suggested Citation:"Appendix 1: Borrelia burgdorferi." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

RESULTS

If a vaccine program for B. burgdorferi were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the QALYs gained would be 200. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the QALYs gained would be 39.

If a vaccine program for B. burgdorferi were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the health care costs saved would be $2 million. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the health care costs saved would be $410,000.

If a vaccine program for B. burgdorferi were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the program cost would be $690 million. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the program cost would be $280 million.

Using committee assumptions of time and costs until licensure, the fixed cost of vaccine development has been amortized and is $3.6 million for a B. burgdorferi vaccine.

If a vaccine program were implemented today and the vaccine were 100% efficacious and utilized by 100% of the target population, the annualized present value of the cost per QALY gained is $3.5 million. Using committee assumptions of less-than-ideal utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the cost per QALY gained is $7.3 million.

See Chapters 4 and 5 for details on the methods and assumptions used by the committee for the results reported.

READING LIST

Byerly E, Deardorff K. National and State Population Estimates: 1990 to 1994, U.S. Bureau of the Census, Current Population Reports, pp. 25–1127, U.S. Government Printing Office, Washington, DC, 1995.


CDC. Summary of Notifiable Diseases, United States 1994. Morbidity and Mortality Weekly Report 1994; 43:1–80.


Hansen KA. Geographical Mobility: March 1993 to March 1994, U.S. Bureau of the Census, Current Population Reports, pp. 20–485, U.S. Government Printing Office, Washington, DC, 1995.

Suggested Citation:"Appendix 1: Borrelia burgdorferi." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×

Stechenberg BW. Borrelia: Lyme Disease. In: Textbook of Pediatric Infectious Diseases. RD Feigin and JD Cherry eds. Philadelphia, PA: WB Saunder Company, 1992, pp. 1062–1067.

Steere AC. Borrelia burgdorferi (Lyme Disease, Lyme Borreliosis). In: Principles and Practice of Infectious Diseases. GL Mandell, JE Bennett, Dolin R eds. New York: Churchill Livingstone, 1995, pp. 2143–2155.


Ventura SJ, Martin JA, Mathews TJ, et al. Advance Report of Final Natality Statistics, 1994. Monthly Vital Statistics Report 1996; 44.


Wormser GP. Prospects for a Vaccine to Prevent Lyme Disease in Humans. Clinical Infectious Diseases 1995; 21:1267–1274.

Suggested Citation:"Appendix 1: Borrelia burgdorferi." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 143
Suggested Citation:"Appendix 1: Borrelia burgdorferi." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 144
Suggested Citation:"Appendix 1: Borrelia burgdorferi." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 145
Suggested Citation:"Appendix 1: Borrelia burgdorferi." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 146
Suggested Citation:"Appendix 1: Borrelia burgdorferi." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 147
Suggested Citation:"Appendix 1: Borrelia burgdorferi." Institute of Medicine. 2000. Vaccines for the 21st Century: A Tool for Decisionmaking. Washington, DC: The National Academies Press. doi: 10.17226/5501.
×
Page 148
Next: Appendix 2: Chlamydia »
Vaccines for the 21st Century: A Tool for Decisionmaking Get This Book
×
Buy Hardback | $72.95 Buy Ebook | $59.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Vaccines have made it possible to eradicate the scourge of smallpox, promise the same for polio, and have profoundly reduced the threat posed by other diseases such as whooping cough, measles, and meningitis.

What is next? There are many pathogens, autoimmune diseases, and cancers that may be promising targets for vaccine research and development.

This volume provides an analytic framework and quantitative model for evaluating disease conditions that can be applied by those setting priorities for vaccine development over the coming decades. The committee describes an approach for comparing potential new vaccines based on their impact on morbidity and mortality and on the costs of both health care and vaccine development. The book examines:

  • Lessons to be learned from the polio experience.
  • Scientific advances that set the stage for new vaccines.
  • Factors that affect how vaccines are used in the population.
  • Value judgments and ethical questions raised by comparison of health needs and benefits.

The committee provides a way to compare different forms of illness and set vaccine priorities without assigning a monetary value to lives. Their recommendations will be important to anyone involved in science policy and public health planning: policymakers, regulators, health care providers, vaccine manufacturers, and researchers.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!